Neprilysin (neutral endopeptidase, enkephalinase, CALLA, CD10, NEP) is a regulatory Zn metallopeptidase expressed in the brush border membranes of the kidney and has been found in porcine chondrocytes and rat articular cartilage as well as other cell types and tissues. Although its function in cartilage is not currently known, previous observations of high levels of NEP enzymatic activity in the synovial fluid of arthritic patients and on the chondrocyte membranes of human osteoarthritic cartilage have led to the hypothesis that NEP is involved in the inflammation or degradation pathways in articular cartilage. Our study localized endogenous NEP to the membranes of mature bovine articular chondrocytes in a tissue explant model and demonstrated that the addition of soluble recombinant NEP (sNEP) to the culture medium of bovine cartilage explants leads to the degradation of aggrecan through the action of aggrecanase. A 6-day exposure to sNEP was necessary to initiate the degradation, suggesting that the chondrocytes were responding in a delayed manner to an altered composition of regulatory peptides. This NEP-induced degradation was completely inhibited by the NEP inhibitors thiorphan and phosphoramidon. These results suggest that NEP is present as a transmembrane enzyme on articular chondrocytes where it can cleave regulatory peptides and lead to the induction of aggrecanase.
Neprilysin is a transmembrane Zn metallopeptidase initially isolated from the brush border membranes of porcine kidneys (1) . This glycosylated enzyme has a molecular weight of 90 -100 kDa, which can vary between tissues and species and possesses the critical HEXXH motif usually associated with the Zn-metalloprotease family (2) . NEP 3 can be expressed in a constitutive fashion as in the kidney or in a regulated manner during development (3) and is particularly abundant in the central nervous system, kidney, placenta, and intestine (3) . Although NEP is usually expressed as a transmembrane protein, some soluble variants have been identified in several physiological fluids (3) and it remains unknown whether these proteins are synthesized in a soluble form or if they result from the shedding of a membrane-bound form. The substrates of neprilysin are typically smaller than 35 amino acids and include atrial natriuretic peptide (ANP), substance P, and enkephalins (3) . ANP is a physiological substrate of neprilysin in the renal and vascular systems where its cleavage leads to vasoconstriction (4) . NEP can also regulate a high number of inflammatory peptides in vivo (5) and is implicated in the inactivation of opioids in the central nervous system (6) .
Neprilysin is expressed in porcine chondrocyte monolayer cultures (7) , in rat articular cartilage (8) , and in human osteoarthritic chondrocytes (9) . After NEP was isolated from the synovial fluid of arthritic patients (10, 11) , the interesting hypothesis emerged that it could play a role as a pain and inflammation modulator in arthritis. It is also known that NEP is expressed by other tissues in the articular joint. For example, NEP expression in synoviocytes is greater in rheumatoid arthritis and degenerative joint disease than after traumatic arthropathy, suggesting a role in human arthritis (12) . Furthermore, it was found that the injection of thiorphan, a NEP inhibitor, in arthritic rats led to a higher pain threshold in a joint inflammation model (13) , suggesting the possibility that neprilysin inhibitors could be used as therapeutic agents for the treatment of arthritis. Finally, in preliminary studies, NEP was able to induce aggrecanase activity when added to the culture medium of rat chondrosarcoma cells, again pointing to its possible involvement in the degradation of articular cartilage (14) .
The starting hypothesis underlying this study was that NEP may play an important, as yet unidentified, role in arthritis. In this study, it was established that NEP is expressed in mature bovine articular cartilage explants as a membrane-bound enzyme and that addition of recombinant soluble NEP to the culture medium of these explants results in aggrecanase-mediated catabolism of aggrecan.
MATERIALS AND METHODS

Materials.
Calcein AM (C-1430) and ethidium homodimer-1 (E-3565) were purchased from Molecular Probes (Eugene, OR). Thiorphan (T-6031) and phosphoramidon (R-7385) were purchased from Sigma (Oakville, ONT, Canada). Soluble recombinant neprilysin (sNEP) was a truncated form of neprilysin, lacking its transmembrane domain, expressed in methylotropic Pichia pastoris yeast. Positive neprilysin controls included purified rabbit neprilysin (15) and MDCK-ENK (Madin-Darby canine kidney) cells transfected with a vector containing cDNA of neprilysin (16) . Peroxidase-labeled goat anti-mouse IgG (HϩL) (PI2000) and peroxidase-labeled goat anti-rabbit IgG (HϩL) (PI1000) were purchased from Vector (Burlington, ONT, Canada). FITC-labeled goat anti-mouse IgG (Fab specific) (F-4018) was purchased from Sigma. Chondroitinase ABC (100332) and keratanase (100810) were purchased from Seikagaku (Tokyo, Japan). Hyaluronidase EC 3.2.1.35 (H-3506) was purchased from Sigma. Interleukin-1␣ (200-LA) was purchased from R&D Systems (Minneapolis, MN). Glucose oxidase grade II (646431) and beef liver catalase (106810) were purchased from Roche Diagnostics (Laval-des-Rapides, QC, Canada). Mowiol (175904) was purchased from Intersciences Inc. (Markham, ONT, Canada). A Biopulverizer was obtained from BioSpec Products (Oklahoma). Primary polyclonal rabbit antibody antisera anti-G1, anti-ARGSV, and anti-NITEGE were provided by J. S. Mort (Joint Diseases Laboratory, Shriners Hospital for Children, Department of Surgery, McGill University, Montreal, QC, Canada).
Isolation and culture of articular cartilage explants. Bovine shoulders were purchased at a local slaughterhouse, 6 -16 h postmortem, from animals ages 1-2 years. The load-bearing region of the shoulder was identified as the circular region of the humeral head that is in direct contact with the opposite articular surface. Preparation of cartilage-bone explants of 4 mm diameter and 1.5 mm thickness from the bovine shoulders was performed as described previously (17) . The bone was retained in order to prevent the cartilage from curling. The cartilage explants were transferred to 48-well culture plates and washed five times in Hanks' balanced saline solution (HBSS) supplemented with 50 g/ml gentamycin.
Viability was analyzed immediately after extraction, using calcein AM and ethidium homodimer-1 as described previously (17) , and revealed only a thin region of two or three layers of dead cells at the articular surface of the bovine explants with the majority of chondrocytes (Ͼ90%) staining as viable. This viability pattern was similar to that observed previously in that long-term stability of this explant culture system in terms of proteoglycan and collagen metabolism was observed for at least 21 days (17) . The explants were cultured in 96-well plates containing 250 l of culture medium (DME/F12 supplemented with 0.01% BSA and 100 g/ml gentamycin) per plate, at 37°C, 95% air, and 5% CO 2 . The culture medium was changed daily for 17 days and, from day 1 of culture and on, 20 g/ml fresh ascorbate was added daily. Finally, different exogenous compounds were added to the culture medium from day 3 of culture on. The six conditions of culture were as follows: control (DME/F12 as above), 40 g/ml sNEP, 1 M thiorphan, 1 M phosphoramidon, 40 g/ml sNEP ϩ 1 M thiorphan, and 40 g/ml sNEP ϩ 1 M phosphoramidon. In the current study we found that the addition of sNEP, thiorphan, or phosphoramidon to the culture medium did not affect the viability of the chondrocytes in the explants throughout the culture period.
Identification of neprilysin in articular cartilage by extraction and immunoprecipitation.
Shavings of articular cartilage (3 g) were homogenized on ice using a Tissue-Tearor homogenizer at 3000 rpm in 10 ml of RIPA radioimmunoassay precipitation buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% sodium deoxycholic acid, 1% Triton X-100, and 0.1% SDS) containing a protease inhibitor cocktail (100 g/ml PMSF, 2 g/ml pepstatin A, 50 g/ml TLCK, and 100 g/ml IAA). The homogenate was placed on a rocker for 1 h at 4°C. After a 30-min centrifugation at 2100g at 4°C, the supernatant containing the solubilized proteins was removed.
Ten milliliters of the cartilage extract was precleared using 10 l of preimmune guinea pig serum and 200 l of hydrated protein A-Sepharose beads. Simultaneously, 15 l of the polyclonal anti-NEP guinea pig antibody was preabsorbed to 200 l of the hydrated protein A-Sepharose beads on ice for 1 h. The prebound beads were rinsed in RIPA buffer, then incubated with 10 ml of the precleared cartilage extract for 16 h at 4°C on a rocker. The immune complexed beads were pelleted, washed with RIPA buffer, and boiled for 5 min in 2ϫ loading buffer before the proteins were resolved by SDS-PAGE using a 6% separation gel and 4% stacking gel. Following transfer, the polyvinylidene fluoride (PVDF) membrane was blocked with a TBS solution containing 5% powdered milk and 0.1% Tween 20 and Western detection proceeded. The primary antibody was a monoclonal mouse anti-NEP 18B5 (18) . The secondary antibody was a peroxidase-labeled goat anti-mouse IgG (HϩL). ECL reagents were used for image development.
Partitioning of soluble proteins from membrane-bound proteins by
Triton X-114. Three grams of articular cartilage were homogenized on ice in 20 ml of 2% Triton X-114, 10 mM Tris, 150 mM NaCl, pH 7.6, using a Tissue-Tearor homogenizer at 3000 rpm and the homogenate was placed on a rocker for 2 h at 4°C. After a 30-min centrifugation at 2100g at 4°C, the supernatant was immersed in a 30°C water bath for 15 min and subsequently centrifuged at 2300g and 20°C for 3 min, leading to the partitioning of the soluble and detergent phases (19) . The detergent phase was washed twice with 1 volume of 0.06% Triton X-114 in Tris-salt buffer and placed in a 30°C water bath for 10 min. After phase separation, the proteins in the detergent phase were precipitated with 10 volumes of ethanol: acetone (1:1) on ice and centrifuged at 2300g for 5 min at 4°C. The proteins in the soluble phase were precipitated with trichloroacetic acid at a final concentration of 10%, centrifuged at 2300g for 10 min at 4°C, and washed once with cold ethanol, once with ethanol:ether (1:1), and once with ether. After centrifugation, the protein pellets in both the detergent and the soluble phases were solubilized in the 2ϫ sample buffer and resolved by SDS-PAGE, and Western detection was performed as described above.
Identification of neprilysin in articular cartilage by immunohistochemistry.
Frozen articular cartilage explants embedded in TissueTek OCT compound were cut into 6-m sections. The sections were fixed with 1% glutataraldehyde in HBSS for 10 min at room temperature. Autofluorescence was quenched by treatment with 5 mg/ml NaBH 4 in HBSS for 7 min at room temperature. The sections were digested with 200 mU/ml chondroitinase ABC and 1 mg/ml hyaluronidase EC 3.2.1.35 for 90 min at 37°C in a humid incubator and blocked for 30 min with 1% BSA in PBS followed by incubation with the monoclonal mouse anti-NEP antibody 2B12 in PBS/BSA 0.1% for 1 h at room temperature (20) . The sections were incubated in the presence of a secondary antibody, FITC-labeled goat anti-mouse IgG (Fab specific) in PBS/BSA 0.1% for 1 h at room temperature, before being washed once for 5 min in a GOC (glucose oxidase catalase) solution and mounted using the Mowiol mounting medium. Fluorescent images (40ϫ) were obtained with a microscope (Zeiss Axiovert 100) equipped with a digital camera (SPOT; Diagnostic Instruments, Sterling Heights, Michigan) and Northern Eclipse software (Empix Imaging, Mississauga, ONT, Canada).
Extraction of the proteoglycans from the articular cartilage explants.
After 17 days of culture, proteoglycans were extracted from each articular cartilage explant in 300 l of 4 M guanidine hydrochloride, 100 mM sodium acetate, pH 6.0, containing a protease inhibitor cocktail (1 mM IAA, 10 g/ml pepstatin A, 1 mM PMSF, and 1 mM EDTA). The extraction occurred with agitation for 48 h at 4°C. The extracts were then dialysed 2 ϫ 24 h against 1 L of 10 mM sodium acetate, pH 6.0, at 4°C for further analysis.
Analysis of GAG content. The guanidine hydrochloride extracts and the culture media were analyzed for their GAG content using the DMMB (dimethylmethylene blue) assay (21) . The samples were diluted to the appropriate concentration (1:1 or 1:2) in a volume of 10 l and placed in a 96-well assay plate before 250 l of the DMMB solution was added. The samples were immediately read in a plate reader (MRX Dynatec Laboratories) at 530 and 590 nm. The difference in absorbance at the two wavelengths was compared to a standard curve of shark chondroitin sulfate diluted in the appropriate buffer. Statistical analysis of GAG content in the guanidine hydrochloride extracts and the culture media was performed using the Student t test.
Analysis of proteoglycan catabolites. One hundred-microliter volumes of the samples (dialyzed GuCl extracts or culture media) were digested with 0.01 U chondroitinase ABC for 4 h at 37°C followed by 0.001 U keratanase for 16 h at 37°C. The digestion was stopped by adding 20 l of 6ϫ sample buffer and the samples were resolved by SDS-PAGE using a 10% separation gel and 4% stacking gel. Following transfer, the PVDF membrane was blocked with a TBS solution containing 5% powdered milk and 0.1% Tween 20 and immunoblotted with the primary polyclonal rabbit antibody antisera anti-G1 (22) , anti-ARGSV (23), and anti-NITEGE (22) . The secondary antibody was a peroxidase-labeled goat anti-rabbit IgG (HϩL). ECL reagents were used as before for image development.
Cleavage of articular cartilage aggrecan by NEP. On the day of isolation of the cartilage explants, proteoglycans were immediately extracted from bovine articular cartilage by freezing the explants in liquid nitrogen, pulverizing the explants using a stainless steel biopulverizer (BioSpec Products) in order to obtain a powder, and incubating them for 5 min at 4°C in 500 l of 4 M guanidine hydrochloride, 100 mM sodium acetate, pH 6.0, containing a protease inhibitor cocktail (1 mM IAA, 10 g/ml pepstatin A, and 1 mM PMSF). After centrifugation for 15 min at 21,000g at 4°C, 100 l of the GuCl extracts was precipitated with 500 l of ethanol at Ϫ20°C for 16 h. The precipitated proteins were centrifuged for 15 min at 21,000g at 4°C, washed with 250 l of 75% ethanol, and resuspended in 100 l of Tris-HCl, 50 mM, pH 7.6. Half the samples were deglycosylated as above. Both the glycosylated and the deglycosylated cartilage protein extracts were incubated in the presence of 100 ng of sNEP at 37°C for 1 h. The digestion was stopped by boiling the samples for 10 min at 100°C. Following a second identical deglycosylation step, the samples were resolved by SDS-PAGE as above and immunoblotted with the primary polyclonal rabbit antibody anti-G1 (22) . The secondary antibody was a peroxidase-labeled goat anti-rabbit IgG (HϩL). ECL reagents were used as before for image development.
RESULTS
Neprilysin Detection in Bovine Articular Cartilage
Whereas Western analysis of approximately 10 g of cartilage extracts revealed no NEP-reactive bands (Fig. 1A, lanes 3 and 4) , immunoprecipitation of approximately 1 mg of total cartilage proteins followed by Western detection revealed the presence of NEP migrating at 100 kDa in both the load-bearing and the (Fig. 1A,  lanes 7 and 8) . NEP was precipitated from the detergent phase of the proteins extracted from bovine articular cartilage and migrated at approximately 100 kDa (Fig. 1B, lane 3) . Precipitates of the Triton X-114-soluble phase harbored no detectable NEP (Fig. 1B,  lane 4) . NEP expressed in MDCK-ENK cells and purified rabbit NEP comigrated with the NEP detected in cartilage extracts at a molecular weight of approximately 100 kDa (Fig. 1A, lanes 1 and 9; Fig. 1B, lanes  1 and 5) . Untransfected MDCK cells were devoid of NEP (Fig. 1A, lanes 2 and 6; Fig. 1B, lane 2) .
Immunohistochemical detection using the 2B12 monoclonal mouse anti-NEP antibody produced intense staining associated with the membranes of articular chondrocytes of the bovine articular cartilage (Fig.  2A) . The staining was limited to the chondrocytes compared to a corresponding white-light Varel (Hoffman modulation contrast) image of the same section of articular cartilage (Fig. 2B) . Control sections incubated in the presence of the secondary antibody alone did not stain (results not shown). Chondrocytes in all three zones of articular cartilage expressed NEP with similar staining intensities (results not shown).
Effect of Soluble Recombinant Neprilysin on the Release of Glycosaminoglycan
GAG release into the culture medium was used as a measure of aggrecan catabolism. In all cultures, a peak in the release of GAG was observed on day 1 and this gradually decreased to level off by day 7 for the control (Fig. 3) . When sNEP was added to the culture medium from day 3 on, the initial GAG release was similar to the control but was increased from day 9 of culture on, reaching a value approximately three times that of the control (Fig. 3) . Student t test analysis indicates that GAG release in the presence of sNEP was significantly greater than control cultures with a P value Ͻ0.01 at day 13, 15, and 17 in culture. Cultures in the presence of sNEP and the inhibitors thiorphan and phosphoramidon, as well as cultures in the presence of the inhibitors alone, produced GAG release profiles similar to the controls (Fig. 3) .
The amount of GAG in tissue extracts after 17 days in culture was also measured. In the presence of sNEP, the GAG content decreased to about 2/3 of the control (Fig. 4) . Student t test analysis indicates that GAG content in the presence of sNEP was significantly decreased compared to control cultures, with a P value Ͻ0.03. In the presence of sNEP and the inhibitors thiorphan and phosphoramidon, as well as in the presence of the inhibitors alone, the quantities of GAG extracted from the explants were not statistically different from the controls (Fig. 4) .
Cleavage of Bovine Cartilage Aggrecan by Soluble Recombinant Neprilysin
The ability of sNEP to directly cleave aggrecan was investigated. Deglycosylated and glycosylated bovine aggrecan extracts were treated with sNEP, resolved by SDS-PAGE, and Western blotted with anti-G1. Exposure of the deglycosylated aggrecan core protein to 100 ng of sNEP for 1 h resulted in an almost complete degradation (Fig. 5A, lane 2) . This cleavage was inhibited when phosphoramidon or thiorphan was simultaneously added with the sNEP (Fig. 5A, lanes 3 and 4) or when phosphoramidon or thiorphan was added alone (Fig. 5A, lanes 5 and 6) . However, when glycosylated aggrecan was exposed to the same amount of sNEP for 1 h, followed by deglycosylation and Western blotting, this degradation was not observed (Fig. 5B,  lane 2) .
Effect of Soluble Recombinant Neprilysin on the Release of Aggrecanase-Generated Aggrecan Fragments
The study of the degradation of cartilage is facilitated by the availability of antibodies specific for products of aggrecan core protein cleavage produced by different proteases (24) . In cartilage cultures, aggrecan is usually cleaved between the interglobular domain separating the G1 and the G2 regions of the proteoglycan. The G1 region can be detected by Western blotting using a general anti-G1 antibody. SDS-PAGE separation of the tissue extracts followed by Western blotting using the polyclonal rabbit anti-G1 antibody revealed the presence of several bands: Ͼ220, 220, 160, 116, 90, and 70 kDa (Fig. 6A) . The staining appeared slightly less intense in the presence of sNEP compared to the other culture conditions, which showed similar staining intensities (Fig. 6A, lane 2) . The same Western profile was observed in seven of eight samples tested under each of the culture conditions. Staining of the tissue extracts with the polyclonal anti-rabbit anti-NITEGE antibody revealed the presence of a doublet migrating at approximately 90 and 70 kDa (Fig. 6B) . The intensity of staining of the doublet was increased in the presence of sNEP compared to the other culture conditions, which showed similar staining intensities (Fig. 6B, lane 2) .
The culture medium was analyzed for the presence of aggrecan fragments using anti-G1, anti-NITEGE, and anti-ARGSV antibodies at day 0, day 9, and day 17 of culture ( Fig. 7) . The G1, NITEGE, and ARGSV fragments were present in varying amounts under all culture conditions at day 0 and day 9. The most striking results were observed in the culture medium at day 17, in which the G1, NITEGE, and ARGSV fragments were detected only in the presence of sNEP and not under the other culture conditions. Culture in the presence of sNEP led to the release into the culture medium of a G1-stained 90-kDa band in all the samples compared to the controls (Fig. 7A, lane 2) . Co-incubation of the explants with sNEP and NEP inhibitors abrogated the (Fig. 7A, lane  3) . The addition of phosphoramidon and sNEP did not lead to the release of the 90-kDa band except in one case. In the presence of thiorphan alone, the 90-kDa band was not released in five of eight samples. In the presence of phosphoramidon alone, the 90-kDa band was not released except in one case. The culture medium was also analyzed for the presence of aggrecan fragments bearing the C-terminal neo-epitope NITEGE produced by aggrecanase. The polyclonal rabbit anti-NITEGE antibody stained the culture medium at day 17 of culture in a fashion identical to that of the polyclonal rabbit anti-G1 antibody. A 90-kDa NITEGEstained fragment could be observed in all the samples when sNEP was added to the culture medium (Fig. 7B,  lane 2) . The release and intensities of the 90-kDa NITEGE-stained bands mirrored those of the G1-stained bands described for Fig. 7A . The culture medium was also analyzed for the presence of aggrecan fragments containing the N-terminal neo-epitope ARGSV produced by the action of aggrecanase. Day 17 culture media harbored several bands recognized by anti-ARGSV that migrated to molecular weights ranging from 170 to Ͼ250 kDa (Fig. 7C) . The presence of sNEP increased the intensities of those bands in seven of eight samples compared to the controls (Fig. 7C, lane  2) . In the presence of sNEP and thiorphan, the intensities of the bands were not increased except in two of eight samples. In the presence of sNEP and phosphoramidon, the intensities of the bands were not increased except in three of eight samples. The presence of thiorphan alone did not increase the intensities of the bands except in one of eight samples. The presence of phosphoramidon alone did not increase the intensities of the bands except in three of eight samples.
DISCUSSION
The objective of this study was to investigate the possible roles of neprilysin in the degradation of articular cartilage. NEP was characterized in mature bovine articular cartilage explants as a membrane-bound protein and the addition of sNEP to the culture medium of these articular cartilage explants led to an increase in the degradation of aggrecan by aggrecanase. NEP was identified as a 100-kDa protein present in both the load-bearing and the non-loadbearing regions of the humeral head of the bovine shoulder. It is known that NEP is a protein whose mass can vary from 90 to 100 kDa due to differential glycosylation (25) . Partitioning of soluble and membrane proteins occurs following tissue solubilization in the nonionic detergent Triton X-114 and heating to 30°C (23) and has been used before to separate the membrane-bound and soluble form of NEP in the mollusc Aplysia californica (26) . Although NEP is generally considered to be a membrane-bound protein, a soluble form has nonetheless been isolated in several human physiological fluids such as amniotic fluid, plasma, and cerebrospinal fluid (27) and from the synovial fluid of osteoarthritic patients (10, 11) . It is possible that NEP is synthesized by chondrocytes and, following shedding, diffuses through the extracellular matrix. However, this seems unlikely since NEP could be precipitated from the detergent phase but not from the soluble phase of our bovine cartilage following Triton X-114 partitioning. Furthermore, the molecular mass of cartilage NEP appeared identical to that of ectopically expressed NEP, which is consistent with cartilage NEP being an unprocessed protein. The membrane-bound localization of NEP was also supported by immunohistochemistry with the antibody 2B12 that binds an extracellular conformational NEP epitope (28) . Altogether these data strongly support the notion that NEP is present in mature bovine articular cartilage as a membrane-bound protein.
It is well known that cultured articular cartilage explants continue to synthesize aggrecan at a rate comparable to that observed in vivo (29) . A full-thickness cartilage/bone explant system was developed (17) and used to study the effect of sNEP addition on articular cartilage culture. No viable cells could be observed in the underlying bone layer in culture, so there is little probability that bone cells could play a role in biological responses in this system (17) . After proteolytic degradation of the core protein, the N-terminal part of aggrecan substituted with several units of GAG presumably becomes free to diffuse out of the extracellular matrix. The addition of sNEP to the culture medium of bovine cartilage explants tripled the release of GAG, which could be the result of a direct or indirect cleavage of aggrecan induced by sNEP. Although Billington et al. previously found that NEP is capable of in vitro cleavage of the denatured and deglycosylated aggrecan core protein at a site different from the aggrecanase cleavage site (30) , its substrates are generally thought to be small peptides rather than proteins as large as aggrecan (3) . We have reproduced the cleavage of deglycosylated aggrecan by sNEP but the glycosylated form of aggrecan was not susceptible to sNEP cleavage. This points to the hypothesis that the aggrecan cleavage observed in cultured cartilage explants in the presence of sNEP is the result of an indirect process and not of the direct action of sNEP on aggrecan. Furthermore, the effect of sNEP on GAG release is delayed and occurs only after a 6-day exposure to the enzyme, which would indicate that sNEP has an indirect effect on aggrecan degradation through the modulation of unidentified regulatory factors controlling aggrecan degradation. It is known that the addition of IL-1 to articular cartilage explants is an efficient way to stimulate aggrecan degradation (31, 32) through aggrecanase cleavage (33) . A previous publication had stated that NEP was able to cleave IL-1 in vitro (34) but some doubt was cast on the specificity of the assay and a subsequent study determined that NEP is not a regulatory enzyme for IL-1-induced responses in articular cartilage (35) . The bovine articular cartilage explants maintained in culture with sNEP and either thiorphan or phosphoramidon released GAG into the culture medium at a rate comparable to that of the controls. The effect of sNEP on bovine articular cartilage was thus specific to the neprilysin enzymatic activity. Interestingly, the inhibition of endogenous NEP by thiorphan or phosphoramidon had no measurable consequence on the degradation of the aggrecan. This suggests that either a soluble form of neprilysin or possibly a drastic overexpression of neprilysin is necessary to induce aggrecan cleavage. Potentially, the addition of exogenous sNEP to the culture medium may represent an acceleration of natural processes in vivo that could create an imbalance of regulatory peptides. Our in vitro model may represent an aggravated form of the slowly developing in vivo situation contributing to the development of arthritic disease.
Western detection of the extracts with anti-G1 antibody indicated that multiple cleavage sites of the core protein exist in this culture system. Two activities termed aggrecanase-1 and -2, which appear to be the major proteolytic enzymes mediating aggrecan core protein degradation, were recently characterized (36, 37) . After aggrecanase cleavage, G1 with the NITEGE terminus is thought to be retained in the matrix while the fragment containing ARGSV is free to diffuse into the synovial fluid (38) . In the current study, fragments containing the neo-epitope ARGSV were identified in the culture medium. The presence of sNEP specifically increased the intensity of the ARGSV bands, indicating an increase in aggrecanase activity. An increase in NITEGE-containing fragments was also observed in the tissue extracts after 17 days of culture in the presence of sNEP, again pointing to an aggrecanase-mediated cleavage of aggrecan. A G1-bearing fragment of 90 kDa was also released into the culture medium at day 17, indicating that an N-terminal fragment was also released into the culture medium in the presence of sNEP. The size of this fragment was consistent with a G1-bearing fragment containing the epitope NITEGE produced by aggrecanase cleavage and released into the medium. This hypothesis was confirmed when the band was stained by the NITEGE antibody. Therefore, the C-terminal fragments and N-terminal fragments of aggrecan were released into the culture medium fol-7 NEPRILYSIN IN ARTICULAR CARTILAGE lowing aggrecanase cleavage, explaining the slight decrease in G1-containing fragments present in the tissue extracts after a 17-day exposure to sNEP. In a recent study submitted for publication (Sztrolovics et al.) , it was shown that the G1 domain is released following aggrecan cleavage by aggrecanase from bovine nasal cartilage cultured in the presence of IL-1␤ or retinoic acid. Furthermore, G1-containing fragments were released from fetal bovine epiphyseal and adult human cartilage cultured in the presence of retinoic acid. The loss of link protein and hyaluronate to the culture medium was also observed in conjunction with the release of G1-containing fragments. It has been proposed that, in the presence of catabolic agents, aggrecan can be released from the cartilage matrix through cleavage of the aggrecan core protein and through the cleavage of hyaluronate, leading to the release of G1-containing fragments into the culture medium. In a few cases, co-incubation of sNEP with the inhibitors thiorphan or phosphoramidon did not prevent the apparent action of sNEP on aggrecan degradation, raising questions as to the specificity of the inhibitors used in this study. Better and more specific NEP inhibitors such as RB104 (39) could be used in future investigations to ensure that only sNEP is inhibited in the explant culture system.
Our observation that sNEP led to an increased release of GAGs into the culture medium suggests that sNEP can lead to an increased degradation of the cartilage matrix, through an as yet unidentified mechanism. Our observation that NITEGE fragments were increased in the articular cartilage explants in the presence of sNEP and that the ARGSV fragments were released only in the presence of sNEP in late culture strongly suggests that, in this in vitro system, sNEP was instrumental in upregulating cleavage of aggrecan by aggrecanase. Because of the delay in observation of aggrecanase-generated aggrecan fragments, it seems probable that NEP is cleaving one or more regulatory factors that in turn influence aggrecanase production or activation. Chondrocytes could then be responding to an alteration in the balance of regulatory peptides that NEP disrupts over time, potentially exacerbating a slow process that occurs in vivo. The identification of new pathways associated with NEP leading to articular cartilage degradation could result in a better understanding of cartilage degradation processes and in the identification of new arthritis therapeutic targets, including for example the modulation of NEP activity with specific inhibitors.
